We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Review · November 02, 2021

Mesenchymal Stem Cells vs Placebo in Multiple Sclerosis

The Lancet Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
Lancet Neurol 2021 Nov 01;20(11)917-929, A Uccelli, A Laroni, R Ali, MA Battaglia, M Blinkenberg, L Brundin, M Clanet, O Fernandez, J Marriot, P Muraro, SM Nabavi, RS Oliveri, E Radue, C Ramo Tello, I Schiavetti, J Sellner, PS Sorensen, MP Sormani, JT Wuerfel, MS Freedman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading